▲Age-specific incidence rate of all cancers in China in 2022, source: reference [1]

▲Trends in mortality rates of specific cancers by gender in China from 2000 to 2018

（left panel for male data, right panel for female data，source: reference [1]

With the continuous improvement of medical technology, the field of cancer treatment is moving towards a more precise and personalized direction, and new treatment methods and technologies are emerging, providing more possibilities for improving the survival rate and quality of life of cancer patients.

According to the Lancet's "Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries", the 5-year survival rate of cancer in China has increased from 30.9% (2003-2005) to 40.5% (2012-2015). Among them, the five-year survival rate of breast cancer changed the most, from 73.1% (2003-2005) to 82% (2012-2015)< H98>^[2]。

Ms. Zhang, a professor of nuclear physics at Tsinghua University, was unfortunately diagnosed with lung cancer in June 2016 and anal canal malignant melanoma in February 2017. However, fortunately, due to early detection and treatment, as well as actively choosing cellular immunotherapy to enhance her immune system post-surgery, Ms. Zhang managed to gain a second chance at life!

►2016: In June, a follow-up chest PET-CT scan indicated "possible lung cancer in the lateral segment of the right lung middle lobe." Consequently, Ms. Zhang underwent a right lung middle lobe resection at Peking University People's Hospital on June 24, 2016. Postoperative pathology revealed invasive adenocarcinoma, predominantly presenting as mucinous adenocarcinoma. The tumor had been partially resected, with a residual tumor size of 1.8×1.3cm. Focal tumor invasion was observed in the visceral pleura, but no clear intravascular thrombus or lymph node metastasis was detected.

►2017: At the beginning of the year, Ms. Zhang experienced bloody and purulent stools, prompting her to undergo colonoscopy at multiple hospitals from January to February 2017. She was ultimately diagnosed with malignant melanoma in the anal canal . On February 25, 2017, she underwent ESD (Endoscopic Submucosal Dissection) at Tsinghua Chang Gung Hospital in Beijing. Postoperative pathology indicated "tumor cells involving the muscularis mucosae, without penetration. No lesions were observed at the base or resection margin, and no intravascular thrombus was detected." Following surgery, she underwent three cycles of chemotherapy at Beijing Cancer Hospital in May 2017, with the chemotherapy regimen consisting of temozolomide and Endostar.

During chemotherapy, Ms. Zhang experienced severe discomfort and was unable to walk on both legs. To ensure her basic quality of life, after weighing the options, she decided to discontinue chemotherapy. Through a recommendation from a Tsinghua University alumnus, Ms. Zhang learned about the vNKT cell therapy offered by Lehe New Medicine.

After comprehensively understanding Ms. Zhang's condition, the Lehe New Medical team provided a comprehensive evaluation and gave the following second diagnosis and treatment suggestions with :

 

 

Summary: Ms. Zhang was diagnosed with dual primary cancers of lung cancer and malignant melanoma. Due to her advanced age and frail physical condition, she was unable to tolerate the side effects of chemotherapy. Fortunately, she promptly opted for vNKT cell therapy. This treatment not only had no significant side effects but also effectively reduced the risk of metastasis and recurrence, enabling Ms. Zhang to achieve a survival period of over 7 years. This is because vNKT cells can precisely target diseased cells, rapidly activate the immune system, and form an immune memory effect, providing long-term immune protection for patients, improving their overall quality of life, and extending their lifespan. Lehexin Medical hopes that this technology can be applied to more cancer patients for the benefit of the public.

Reference source:

[1]Bingfeng Han, Rongshou Zheng, Hongmei Zeng … &He J. (2022). Cancer incidence and mortality in China, 202［R

[2] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries[J]. The Lancet Global Health, 2018, 6(5): e555-e567.

Contact Us 

Scan QR Code

Communicate with Professor Zhang Minghui's Team

Click on the image to view past exciting content

Contributor: Liu Fengmei

Reviewed by: Qiao Jiacheng, Wang Ying, Gao Chen

Editor/Typesetter: Liu Fengmei

   

Reposting is a driving force, sharing is a virtue